Article info

Download PDFPDF

Original research
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

Authors

  1. Correspondence to Dr Malin Pedersen; malin.pedersen{at}icr.ac.uk
View Full Text

Citation

Crespo-Rodriguez E, Bergerhoff K, Bozhanova G, et al
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

Publication history

  • Accepted May 12, 2020
  • First published August 5, 2020.
Online issue publication 
August 05, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.